Sanofi and Recipharm announce transfer of Holmes Chapel Manufacturing site
Recipharm and Sanofi announced today that they have signed an agreement to transfer the Holmes Chapel site from global healthcare leader, Sanofi, to leading pharmaceutical contract development and manufacturing organisation, Recipharm.
“Holmes Chapel brings Recipharm an ideal opportunity to accelerate its offering to customers with access to novel respiratory products. As an already successful CMO with several clients, we look forward to introducing new contracts to Holmes Chapel by utilising our growing franchise in development services. Treatments for asthma and chronic obstructive pulmonary disease (COPD) are growing at a fast rate and we see many opportunities. The experienced management team and staff have already successfully attracted new customers and we look forward to building on this from the well invested facility” said Thomas Eldered, CEO of Recipharm.
“We are delighted that the Holmes Chapel site is being bought by a company who will further develop the site and its employees, and bring opportunities to utilise the existing technologies and capabilities” said Volker Keuth, Head of Cartridge Division & Emerging Markets, at Sanofi.
The Holmes Chapel manufacturing facility is one of the leading sites of its type in Europe and is home to a team of more than 450 specialist employees. All employees will automatically transfer to Recipharm.
The transaction is expected to close in Q4 2018, after customary licences and permissions have been obtained.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
